Medindia

X

Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer

Saturday, June 5, 2010 Cancer News J E 4
Advertisement
The Third Of Three Pivotal Head-To-Head Trials Submitted To FDA For Treatment Of Patients With Bone Metastases

CONTACT: Amgen, Thousand Oaks

Lisa Rooney: + 1 (805) 559-0739 (media)

Arvind Sood: +1 (805) 447-1060 (investors)

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Adding Novartis Drug ZometaŪ to Chemotherapy Signi...
S
New Analyses of Denosumab Pivotal Phase 3 Trials R...